DK3126528T3 - Fremgangsmåder til bestemmelse af modtagelighed over for MEK/ERK-inhibitorer - Google Patents
Fremgangsmåder til bestemmelse af modtagelighed over for MEK/ERK-inhibitorer Download PDFInfo
- Publication number
- DK3126528T3 DK3126528T3 DK15773840.2T DK15773840T DK3126528T3 DK 3126528 T3 DK3126528 T3 DK 3126528T3 DK 15773840 T DK15773840 T DK 15773840T DK 3126528 T3 DK3126528 T3 DK 3126528T3
- Authority
- DK
- Denmark
- Prior art keywords
- mek
- methods
- erk inhibitors
- determining susceptibility
- susceptibility
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410135569 | 2014-04-04 | ||
| PCT/CN2015/075884 WO2015149721A1 (en) | 2014-04-04 | 2015-04-03 | Methods for determining responsiveness to mek/erk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3126528T3 true DK3126528T3 (da) | 2021-11-08 |
Family
ID=54239415
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15772589.6T DK3126521T3 (da) | 2014-04-04 | 2015-04-03 | HNF4G-RSPO2-fusionsgen |
| DK15773840.2T DK3126528T3 (da) | 2014-04-04 | 2015-04-03 | Fremgangsmåder til bestemmelse af modtagelighed over for MEK/ERK-inhibitorer |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15772589.6T DK3126521T3 (da) | 2014-04-04 | 2015-04-03 | HNF4G-RSPO2-fusionsgen |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10683550B2 (da) |
| EP (3) | EP4012049A3 (da) |
| CN (3) | CN106460060B (da) |
| DK (2) | DK3126521T3 (da) |
| ES (2) | ES2727374T3 (da) |
| PT (2) | PT3126521T (da) |
| WO (2) | WO2015149720A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109563550A (zh) * | 2016-08-04 | 2019-04-02 | 静冈县 | 判定有无癌症发病风险的方法 |
| CN110139875B (zh) * | 2016-09-30 | 2023-03-03 | 武汉华大吉诺因生物科技有限公司 | Col14a1衍生的肿瘤抗原多肽及其应用 |
| US20220088016A1 (en) * | 2019-01-02 | 2022-03-24 | Zhejiang Crownmab Biotech Co. Ltd. | Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers |
| CN111434353A (zh) * | 2019-02-02 | 2020-07-21 | 中国科学院上海营养与健康研究所 | Ras抑制剂筛选及疗效标志物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4503035B1 (en) | 1978-11-24 | 1996-03-19 | Hoffmann La Roche | Protein purification process and product |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
| EP0390323B2 (en) | 1989-03-29 | 2012-08-08 | Johns Hopkins University | Detection of loss of the wild-type p53 gene |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| CN1202932A (zh) | 1995-10-23 | 1998-12-23 | 儿童医学中心公司 | 治疗用抗血管生成的组合物和方法 |
| AU707636C (en) | 1995-11-23 | 2003-01-16 | Cancer Research Campaign Technology Limited | Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
| ES2239393T3 (es) | 1997-05-07 | 2005-09-16 | Sugen, Inc. | Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa. |
| JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| CN101328186A (zh) | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
| US6395734B1 (en) | 1998-05-29 | 2002-05-28 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| DK2050749T3 (da) | 2006-08-08 | 2018-01-08 | Chugai Pharmaceutical Co Ltd | Pyrimidinderivat som pi3k-inhibitor og anvendelse deraf |
| CA2662508A1 (en) * | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| CL2009000241A1 (es) | 2008-02-07 | 2010-09-03 | Chugai Pharmaceutical Co Ltd | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. |
| CN101524529B (zh) | 2008-03-04 | 2011-09-28 | 中国人民解放军第二军医大学 | HNF4α诱导分化治疗人体恶性实体瘤 |
| WO2010096660A2 (en) | 2009-02-19 | 2010-08-26 | Cornell University | Compositions and methods for diagnosing prostate cancer based on detection of slc45a3-elk4 fusion transcript |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| US8945556B2 (en) | 2010-11-19 | 2015-02-03 | The Regents Of The University Of Michigan | RAF gene fusions |
| BR112013012485A2 (pt) | 2010-11-19 | 2016-09-06 | Glaxosmithkline Ip No 2 Ltd | método de tratamento com inibidor braf |
| WO2012106559A1 (en) * | 2011-02-02 | 2012-08-09 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
| CN103571848B (zh) | 2012-08-10 | 2016-06-29 | 安徽医科大学第一附属医院 | 点状掌跖角化病的致病基因及其用途 |
-
2015
- 2015-04-03 CN CN201580029656.9A patent/CN106460060B/zh active Active
- 2015-04-03 PT PT15772589T patent/PT3126521T/pt unknown
- 2015-04-03 EP EP21170371.5A patent/EP4012049A3/en not_active Withdrawn
- 2015-04-03 CN CN202010591503.6A patent/CN111808957A/zh active Pending
- 2015-04-03 CN CN201580028218.0A patent/CN106536753B/zh active Active
- 2015-04-03 EP EP15772589.6A patent/EP3126521B1/en active Active
- 2015-04-03 ES ES15772589T patent/ES2727374T3/es active Active
- 2015-04-03 DK DK15772589.6T patent/DK3126521T3/da active
- 2015-04-03 WO PCT/CN2015/075882 patent/WO2015149720A1/en active Application Filing
- 2015-04-03 EP EP15773840.2A patent/EP3126528B1/en active Active
- 2015-04-03 DK DK15773840.2T patent/DK3126528T3/da active
- 2015-04-03 PT PT157738402T patent/PT3126528T/pt unknown
- 2015-04-03 US US15/301,381 patent/US10683550B2/en active Active
- 2015-04-03 ES ES15773840T patent/ES2896404T3/es active Active
- 2015-04-03 WO PCT/CN2015/075884 patent/WO2015149721A1/en active Application Filing
- 2015-04-03 US US15/301,379 patent/US10501805B2/en active Active
-
2019
- 2019-10-30 US US16/667,932 patent/US20200123622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3126521T3 (da) | 2019-06-17 |
| EP3126521A1 (en) | 2017-02-08 |
| PT3126521T (pt) | 2019-06-27 |
| CN106536753B (zh) | 2020-07-21 |
| EP4012049A2 (en) | 2022-06-15 |
| PT3126528T (pt) | 2021-09-09 |
| US10501805B2 (en) | 2019-12-10 |
| EP3126528B1 (en) | 2021-08-18 |
| WO2015149720A1 (en) | 2015-10-08 |
| EP3126528A1 (en) | 2017-02-08 |
| ES2896404T3 (es) | 2022-02-24 |
| CN111808957A (zh) | 2020-10-23 |
| US20200123622A1 (en) | 2020-04-23 |
| US20180282814A1 (en) | 2018-10-04 |
| US10683550B2 (en) | 2020-06-16 |
| EP4012049A3 (en) | 2022-08-24 |
| EP3126521B1 (en) | 2019-03-20 |
| ES2727374T3 (es) | 2019-10-15 |
| EP3126521A4 (en) | 2017-11-08 |
| US20170114414A1 (en) | 2017-04-27 |
| CN106460060B (zh) | 2020-02-11 |
| EP3126528A4 (en) | 2018-02-21 |
| WO2015149721A1 (en) | 2015-10-08 |
| CN106460060A (zh) | 2017-02-22 |
| CN106536753A (zh) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002736A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| DK3186376T3 (da) | Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3116533T3 (da) | Deletion af dystrophingenexon under anvendelse af genmanipulerede nukleaser | |
| DK3108009T3 (da) | Fremgangsmåder og sammensætninger til DNA-profilering | |
| DK3074534T3 (da) | Fremgangsmåder til polynukleotidsekventering | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3201361T3 (da) | Fremgangsmåder til kvantificering af cellefrit DNA | |
| CL2016002638A1 (es) | Nuevos inhibidores de la nitrificación | |
| DK3160952T3 (da) | Histone demethylase inhibitors | |
| DK3191487T3 (da) | Spirocykliske cathepsin-c-inhibitorer | |
| DK3314010T3 (da) | Fremgangsmåde til detektering af kromosomaberrationer | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| BR112017005128A2 (pt) | inibidores de histona desmetilase | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3212802T3 (da) | Fremgangsmåde til detektering af kontamination med hussvamp | |
| DK3186640T3 (da) | Fremgangsmåde til påvisning af anomalier i hæmoglobin | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3177931T3 (da) | Fremgangsmåde til bestemmelse af stoffers evne til at binde til analytaktive steder | |
| DK3748358T3 (da) | Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid |